The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels

(2013) Alessandro Ciresi et al.   CLINICAL ENDOCRINOLOGY

The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women

(2012) Jameason D. Cameron et al.   APPETITE

Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas

(2012) A P Athanasoulia et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on α2-adrenergic receptor in 3T3-L1 adipocyte cells

(2012) Rajib Mukherjee et al.   MOLECULAR BIOLOGY REPORTS

Distinct Dopaminergic Personality Patterns in Patients with Prolactinomas: A Comparison with Nonfunctioning Pituitary Adenoma Patients and Age- and Gender-Matched Controls

(2012) A.P. Athanasoulia et al.   NEUROENDOCRINOLOGY

TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients

(2012) Julia K. Winkler et al.   NUTRITION

Dopamine Genes (DRD2/ANKK1-TaqA1 and DRD4-7R) and Executive Function: Their Interaction with Obesity

(2012) Mar Ariza et al.   PLoS One

Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults

(2011) C. D. Gibson et al.   DIABETES OBESITY & METABOLISM

Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline

(2011) Shlomo Melmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dopamine Receptors in Human Adipocytes: Expression and Functions

(2011) Dana C. Borcherding et al.   PLoS One

BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists

(2010) Cintia M. dos Santos Silva et al.   Obesity

Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy

(2010) Katarina Berinder et al.   Pituitary

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

(2010) Via   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Significant Association of ANKK1 and Detection of a Functional Polymorphism with Nicotine Dependence in an African-American Sample

(2008) Weihua Huang et al.   NEUROPSYCHOPHARMACOLOGY

Relation Between Obesity and Blunted Striatal Response to Food Is Moderated by TaqIA A1 Allele

(2008) E. Stice et al.   SCIENCE